Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension

Song Yi Kim, Seung Jae Joo, Mi Seung Shin, Changsoo Kim, Eun Joo Cho, Ki Chul Sung, Seok Min Kang, Dong Soo Kim, Seung Hwan Lee, Kyung Kuk Hwang, Jeong Bae Park

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin-angiotensin-aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this effect. This study aimed to investigate clinic and home blood pressure (BP) lowering effect of fimasartan, a new angiotensin receptor blocker, in postmenopausal women with hypertension. Among patients with hypertension enrolled in K-Mets Study, 1373 women with fimasartan as a first antihypertensive drug and 3-months follow-up data were selected. They were divided into 2 groups; premenopausal women (pre-MPW; n=382, 45.3±4.6 years) and postmenopausal women (post-MPW; n=991, 60.9±8.2 years). Baseline clinic systolic BP was not different (pre-MPW; 152.9±15.2 vs. post-MPW; 152.8±13.5 mm Hg), but diastolic BP was lower in post-MPW (pre-MPW; 95.7±9.4 vs. post-MPW; 91.9±9.4 mm Hg, P<0.001). After 3-month treatment, clinic BP declined effectively without significant differences between 2 groups (Δsystolic/diastolic BP: pre-MPW; -25.7±17.7/-14.2±11.3 vs. post-MPW; -25.7±16.3/-13.1±10.9 mm Hg). Home morning and evening systolic BP decreased similarly in both groups (Δmorning/evening systolic BP: pre-MPW; -21.3±17.9/-23.1±15.8 vs. post-MPW; -20.4±17.3/-20.2±19.2 mm Hg). Fimasartan also significantly decreased the standard deviations of home morning and evening systolic BP of pre-MPW and post-MPW. Fimasartan was a similarly effective BP lowering agent in both post-MPW and pre-MPW with hypertension, and it also decreased day-to-day BP variability.

Original languageEnglish
Article numbere3764
JournalMedicine (United States)
Volume95
Issue number22
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Angiotensin Receptor Antagonists
Blood Pressure
Hypertension
fimasartan
Renin-Angiotensin System
Antihypertensive Agents

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Song Yi ; Joo, Seung Jae ; Shin, Mi Seung ; Kim, Changsoo ; Cho, Eun Joo ; Sung, Ki Chul ; Kang, Seok Min ; Kim, Dong Soo ; Lee, Seung Hwan ; Hwang, Kyung Kuk ; Park, Jeong Bae. / Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension. In: Medicine (United States). 2016 ; Vol. 95, No. 22.
@article{f3cf718cf0984711a56c0fd7cf3923d5,
title = "Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension",
abstract = "Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin-angiotensin-aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this effect. This study aimed to investigate clinic and home blood pressure (BP) lowering effect of fimasartan, a new angiotensin receptor blocker, in postmenopausal women with hypertension. Among patients with hypertension enrolled in K-Mets Study, 1373 women with fimasartan as a first antihypertensive drug and 3-months follow-up data were selected. They were divided into 2 groups; premenopausal women (pre-MPW; n=382, 45.3±4.6 years) and postmenopausal women (post-MPW; n=991, 60.9±8.2 years). Baseline clinic systolic BP was not different (pre-MPW; 152.9±15.2 vs. post-MPW; 152.8±13.5 mm Hg), but diastolic BP was lower in post-MPW (pre-MPW; 95.7±9.4 vs. post-MPW; 91.9±9.4 mm Hg, P<0.001). After 3-month treatment, clinic BP declined effectively without significant differences between 2 groups (Δsystolic/diastolic BP: pre-MPW; -25.7±17.7/-14.2±11.3 vs. post-MPW; -25.7±16.3/-13.1±10.9 mm Hg). Home morning and evening systolic BP decreased similarly in both groups (Δmorning/evening systolic BP: pre-MPW; -21.3±17.9/-23.1±15.8 vs. post-MPW; -20.4±17.3/-20.2±19.2 mm Hg). Fimasartan also significantly decreased the standard deviations of home morning and evening systolic BP of pre-MPW and post-MPW. Fimasartan was a similarly effective BP lowering agent in both post-MPW and pre-MPW with hypertension, and it also decreased day-to-day BP variability.",
author = "Kim, {Song Yi} and Joo, {Seung Jae} and Shin, {Mi Seung} and Changsoo Kim and Cho, {Eun Joo} and Sung, {Ki Chul} and Kang, {Seok Min} and Kim, {Dong Soo} and Lee, {Seung Hwan} and Hwang, {Kyung Kuk} and Park, {Jeong Bae}",
year = "2016",
month = "5",
day = "1",
doi = "10.1097/MD.0000000000003764",
language = "English",
volume = "95",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "22",

}

Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension. / Kim, Song Yi; Joo, Seung Jae; Shin, Mi Seung; Kim, Changsoo; Cho, Eun Joo; Sung, Ki Chul; Kang, Seok Min; Kim, Dong Soo; Lee, Seung Hwan; Hwang, Kyung Kuk; Park, Jeong Bae.

In: Medicine (United States), Vol. 95, No. 22, e3764, 01.05.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinic and home blood pressure lowering effect of an angiotensin receptor blocker, fimasartan, in postmenopausal women with hypertension

AU - Kim, Song Yi

AU - Joo, Seung Jae

AU - Shin, Mi Seung

AU - Kim, Changsoo

AU - Cho, Eun Joo

AU - Sung, Ki Chul

AU - Kang, Seok Min

AU - Kim, Dong Soo

AU - Lee, Seung Hwan

AU - Hwang, Kyung Kuk

AU - Park, Jeong Bae

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin-angiotensin-aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this effect. This study aimed to investigate clinic and home blood pressure (BP) lowering effect of fimasartan, a new angiotensin receptor blocker, in postmenopausal women with hypertension. Among patients with hypertension enrolled in K-Mets Study, 1373 women with fimasartan as a first antihypertensive drug and 3-months follow-up data were selected. They were divided into 2 groups; premenopausal women (pre-MPW; n=382, 45.3±4.6 years) and postmenopausal women (post-MPW; n=991, 60.9±8.2 years). Baseline clinic systolic BP was not different (pre-MPW; 152.9±15.2 vs. post-MPW; 152.8±13.5 mm Hg), but diastolic BP was lower in post-MPW (pre-MPW; 95.7±9.4 vs. post-MPW; 91.9±9.4 mm Hg, P<0.001). After 3-month treatment, clinic BP declined effectively without significant differences between 2 groups (Δsystolic/diastolic BP: pre-MPW; -25.7±17.7/-14.2±11.3 vs. post-MPW; -25.7±16.3/-13.1±10.9 mm Hg). Home morning and evening systolic BP decreased similarly in both groups (Δmorning/evening systolic BP: pre-MPW; -21.3±17.9/-23.1±15.8 vs. post-MPW; -20.4±17.3/-20.2±19.2 mm Hg). Fimasartan also significantly decreased the standard deviations of home morning and evening systolic BP of pre-MPW and post-MPW. Fimasartan was a similarly effective BP lowering agent in both post-MPW and pre-MPW with hypertension, and it also decreased day-to-day BP variability.

AB - Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin-angiotensin-aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this effect. This study aimed to investigate clinic and home blood pressure (BP) lowering effect of fimasartan, a new angiotensin receptor blocker, in postmenopausal women with hypertension. Among patients with hypertension enrolled in K-Mets Study, 1373 women with fimasartan as a first antihypertensive drug and 3-months follow-up data were selected. They were divided into 2 groups; premenopausal women (pre-MPW; n=382, 45.3±4.6 years) and postmenopausal women (post-MPW; n=991, 60.9±8.2 years). Baseline clinic systolic BP was not different (pre-MPW; 152.9±15.2 vs. post-MPW; 152.8±13.5 mm Hg), but diastolic BP was lower in post-MPW (pre-MPW; 95.7±9.4 vs. post-MPW; 91.9±9.4 mm Hg, P<0.001). After 3-month treatment, clinic BP declined effectively without significant differences between 2 groups (Δsystolic/diastolic BP: pre-MPW; -25.7±17.7/-14.2±11.3 vs. post-MPW; -25.7±16.3/-13.1±10.9 mm Hg). Home morning and evening systolic BP decreased similarly in both groups (Δmorning/evening systolic BP: pre-MPW; -21.3±17.9/-23.1±15.8 vs. post-MPW; -20.4±17.3/-20.2±19.2 mm Hg). Fimasartan also significantly decreased the standard deviations of home morning and evening systolic BP of pre-MPW and post-MPW. Fimasartan was a similarly effective BP lowering agent in both post-MPW and pre-MPW with hypertension, and it also decreased day-to-day BP variability.

UR - http://www.scopus.com/inward/record.url?scp=84975260803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975260803&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000003764

DO - 10.1097/MD.0000000000003764

M3 - Article

C2 - 27258507

AN - SCOPUS:84975260803

VL - 95

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 22

M1 - e3764

ER -